Delving into the Latest Updates on Obe Therapy Biotechnology SAS with Synapse

概览

关联

1

项与 Obe Therapy Biotechnology SAS 相关的药物

OBE-2001

靶点

enteropeptidase

作用机制

enteropeptidase抑制剂

在研机构-

原研机构

Obe Therapy Biotechnology SAS

在研适应症-

非在研适应症

2型糖尿病 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Obe Therapy Biotechnology SAS 相关的临床结果

登录后查看更多信息

0 项与 Obe Therapy Biotechnology SAS 相关的专利（医药）

登录后查看更多信息

1

项与 Obe Therapy Biotechnology SAS 相关的文献（医药）

2010-12-01·Future Medicinal Chemistry4区 · 医学

‘Energy Expenditure Genes’ or ‘Energy Absorption Genes’: A New Target for the Treatment of Obesity and Type II Diabetes

4区 · 医学

Article

作者: Braud, Sandrine ; Harosh, Itzik ; Ciufolini, Marco

Several hundred genes associated or linked to obesity have been described in the scientific literature. Whereas many of these genes are potential targets for the treatment of obesity and associated conditions, none of them have permitted the developement of an efficient drug therapy. As proposed by the ‘thrifty genotype’ theory, obesity genes may have conferred an evolutionary advantage in times of food shortage through efficient energy exploitation, while ‘lean’ or ‘energy expenditure’ genes may have become very rare during the same periods. It is therefore a challenge to identify ‘energy expenditure genes’ or ‘energy absorption genes,’ whose mutations or single nucleotide polymorphisms do result in reduced energy intake. We submit that such ‘energy absorption’ or ‘energy expenditure’ genes (crucial genes) are potential new targets for the treatment of obesity. These genes can be identified in rare genetic diseases that produce a lean, failure-to-thrive, energy malabsorption or starvation phenotype.

100 项与 Obe Therapy Biotechnology SAS 相关的药物交易

登录后查看更多信息

100 项与 Obe Therapy Biotechnology SAS 相关的转化医学

登录后查看更多信息